Prescription rebates have the potential to benefit patients, but under the current drug pricing system, patients may pay even more for their medicines.
In 2018, Pfizer paid about $12 billion in rebates. But these rebates did not go directly to patients.
Why not? In the current rebate system, insurers and pharmacy benefit managers (PBMs) negotiate discounts with pharmaceutical companies. But these middlemen are often keeping the rebates for themselves instead of passing the savings on to customers, leaving patients to pay higher costs at the pharmacy counter.
Congress must work to revise our broken system and support transparent, upfront discounts that directly benefit patients. Join the Ready for Cures community to receive updates on how you can help advocate for prescription drug rebate reform and other policies that could lower out-of-pocket costs for patients.